BRPI0408372A - potencializador de efeito antitumor e agente antitumor - Google Patents
potencializador de efeito antitumor e agente antitumorInfo
- Publication number
- BRPI0408372A BRPI0408372A BRPI0408372-5A BRPI0408372A BRPI0408372A BR PI0408372 A BRPI0408372 A BR PI0408372A BR PI0408372 A BRPI0408372 A BR PI0408372A BR PI0408372 A BRPI0408372 A BR PI0408372A
- Authority
- BR
- Brazil
- Prior art keywords
- antitumor
- antitumor effect
- agent
- administering
- enhancing
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title abstract 8
- 239000002246 antineoplastic agent Substances 0.000 title abstract 4
- 239000003623 enhancer Substances 0.000 title 1
- 230000002708 enhancing effect Effects 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 abstract 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 abstract 1
- ZPLQIPFOCGIIHV-UHFFFAOYSA-N Gimeracil Chemical compound OC1=CC(=O)C(Cl)=CN1 ZPLQIPFOCGIIHV-UHFFFAOYSA-N 0.000 abstract 1
- IAPCTXZQXAVYNG-UHFFFAOYSA-M Potassium 2,6-dihydroxytriazinecarboxylate Chemical compound [K+].[O-]C(=O)C1=NC(=O)NC(=O)N1 IAPCTXZQXAVYNG-UHFFFAOYSA-M 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 abstract 1
- 235000008191 folinic acid Nutrition 0.000 abstract 1
- 239000011672 folinic acid Substances 0.000 abstract 1
- 229950009822 gimeracil Drugs 0.000 abstract 1
- 229960001691 leucovorin Drugs 0.000 abstract 1
- 229950000193 oteracil Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 abstract 1
- 229960001674 tegafur Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
"POTENCIALIZADOR DE EFEITO ANTITUMOR E AGENTE ANTITUMOR". A presente invenção provê um potencializador de efeito antitumor para intensificação de atividade antitumor de um agente antitumor compreendendo tegafur em uma quantidade terapeuticamente eficaz, gimeracil em uma quantidade eficaz para intensificação de um efeito antitumor, e potássio de oteracila em uma quantidade eficaz para inibição de um efeito colateral, o potencializador de efeito antitumor compreendendo pelo menos um membro selecionado do grupo consistindo em ácido folínico e seus sais farmacologicamente aceitáveis em uma quantidade eficaz para intensificação de um efeito antitumor; um agente antitumor compreendendo, como ingredientes ativos, tegafur em uma quantidade terapeuticamente eficaz, gimeracil em uma quantidade eficaz para intensificação de um efeito antitumor, potássio de oteracila em uma quantidade eficaz para inibição de um efeito colateral, e pelo menos um membro selecionado do grupo consistindo em ácido folínico e seus sais farmacologicamente aceitáveis em uma quantidade eficaz para intensificação de um efeito antitumor; um processo para intensificação de um efeito antitumor de um agente antitumor compreendendo a etapa de administração a um paciente do potencializador de efeito antitumor mencionado anteriormente; e um processo para tratamento de câncer compreendendo a etapa de administração a um paciente do agente antitumor mencionado anteriormente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2003070097 | 2003-03-14 | ||
| PCT/JP2004/003189 WO2004081012A1 (ja) | 2003-03-14 | 2004-03-11 | 抗腫瘍効果増強剤及び抗腫瘍剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0408372A true BRPI0408372A (pt) | 2006-03-21 |
Family
ID=32984641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0408372-5A BRPI0408372A (pt) | 2003-03-14 | 2004-03-11 | potencializador de efeito antitumor e agente antitumor |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US9611227B2 (pt) |
| EP (1) | EP1604991B1 (pt) |
| JP (1) | JP4610481B2 (pt) |
| KR (1) | KR100812693B1 (pt) |
| CN (2) | CN1761665A (pt) |
| AT (1) | ATE408408T1 (pt) |
| AU (1) | AU2004220205B2 (pt) |
| BR (1) | BRPI0408372A (pt) |
| CA (1) | CA2518195C (pt) |
| CY (1) | CY1108395T1 (pt) |
| DE (1) | DE602004016636D1 (pt) |
| DK (1) | DK1604991T3 (pt) |
| ES (1) | ES2312978T3 (pt) |
| MX (1) | MXPA05009781A (pt) |
| NZ (1) | NZ542150A (pt) |
| PL (1) | PL1604991T3 (pt) |
| PT (1) | PT1604991E (pt) |
| RU (1) | RU2334517C2 (pt) |
| SI (1) | SI1604991T1 (pt) |
| TW (1) | TW200503720A (pt) |
| WO (1) | WO2004081012A1 (pt) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2415670C2 (ru) * | 2005-04-01 | 2011-04-10 | Тайхо Фармасьютикал Ко., Лтд. | Усиливающий агент для радиационной терапии, включающий производное пиридина в качестве активного ингредиента |
| EP1864683B1 (en) * | 2005-04-01 | 2010-09-01 | Taiho Pharmaceutical Co., Ltd. | Radiotherapy enhancer |
| JPWO2007043531A1 (ja) * | 2005-10-07 | 2009-04-16 | セレスター・レキシコ・サイエンシズ株式会社 | 抗腫瘍剤及び放射線併用療法感受性診断用遺伝子マーカー並びにその利用 |
| WO2009139085A1 (ja) * | 2008-05-12 | 2009-11-19 | 静岡県 | 抗腫瘍剤、キット及び癌治療方法 |
| JP5553522B2 (ja) * | 2009-03-31 | 2014-07-16 | 大鵬薬品工業株式会社 | 経口投与用医薬組成物 |
| JP5566376B2 (ja) * | 2009-04-22 | 2014-08-06 | 大鵬薬品工業株式会社 | 腎細胞癌に対する化学療法の治療効果予測方法 |
| CN102309491B (zh) * | 2010-07-02 | 2015-06-10 | 天津金耀集团有限公司 | 一种替加氟、吉美斯特复方注射液 |
| JP5689173B2 (ja) * | 2011-05-25 | 2015-03-25 | 大鵬薬品工業株式会社 | テガフール、ギメラシル、オテラシルカリウム含有有核錠 |
| PL3053578T3 (pl) * | 2013-09-30 | 2021-06-14 | Taiho Pharmaceutical Co., Ltd. | Skojarzona terapia przeciwnowotworowa z zastosowaniem związku azabicyklicznego |
| CN106692173A (zh) * | 2015-11-18 | 2017-05-24 | 北京诺普德医药科技有限公司 | 一种抗肿瘤复方组合物及其应用 |
| CN106581001B (zh) * | 2016-11-03 | 2018-12-21 | 江苏恒瑞医药股份有限公司 | 一种替吉奥组合物的制备方法 |
| KR102258514B1 (ko) | 2019-09-23 | 2021-05-31 | 연세대학교 산학협력단 | 신규한 다층형 좌약 제제 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5116600A (en) | 1989-01-05 | 1992-05-26 | Otsuka Pharmaceutical Co., Ltd. | Composition and method for inhibiting inflammation caused by non-parenteral administration of 5-fluorouracil type compounds |
| WO1992004028A1 (en) | 1990-09-07 | 1992-03-19 | Taiho Pharmaceutical Company, Limited | Antineoplastic effect potentiator and antineoplastic agent |
| CA2087540C (en) | 1991-05-27 | 1999-01-19 | Taiho Pharmaceutical Co., Ltd. | Composition, method and kit for potentiating antitumor activity and for curing tumor |
| CH683262A5 (it) * | 1992-01-22 | 1994-02-15 | Applied Pharma Res | Procedimento per la separazione dei diastereomeri del sale di calcio dell'acido (6(R,S)-N-formiltetraidrofolico). |
| WO2001066102A2 (en) * | 2000-03-08 | 2001-09-13 | Bristol-Myers Squibb Company | Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same |
| CZ20032266A3 (cs) | 2001-03-06 | 2004-02-18 | Bristol-Myers Squibb Company | Dávkovací formy pro ošetřování nádorů |
| EP1411120B1 (en) * | 2001-07-05 | 2010-01-13 | Taiho Pharmaceutical Company Limited | Dna arrays for measuring sensitivity to anticancer agent |
-
2004
- 2004-03-11 BR BRPI0408372-5A patent/BRPI0408372A/pt not_active Application Discontinuation
- 2004-03-11 US US10/548,655 patent/US9611227B2/en not_active Expired - Fee Related
- 2004-03-11 DK DK04719589T patent/DK1604991T3/da active
- 2004-03-11 JP JP2005503567A patent/JP4610481B2/ja not_active Expired - Lifetime
- 2004-03-11 ES ES04719589T patent/ES2312978T3/es not_active Expired - Lifetime
- 2004-03-11 MX MXPA05009781A patent/MXPA05009781A/es active IP Right Grant
- 2004-03-11 KR KR1020057017150A patent/KR100812693B1/ko not_active Expired - Lifetime
- 2004-03-11 WO PCT/JP2004/003189 patent/WO2004081012A1/ja not_active Ceased
- 2004-03-11 PL PL04719589T patent/PL1604991T3/pl unknown
- 2004-03-11 DE DE602004016636T patent/DE602004016636D1/de not_active Expired - Lifetime
- 2004-03-11 CN CNA2004800069779A patent/CN1761665A/zh active Pending
- 2004-03-11 EP EP04719589A patent/EP1604991B1/en not_active Expired - Lifetime
- 2004-03-11 CA CA002518195A patent/CA2518195C/en not_active Expired - Fee Related
- 2004-03-11 SI SI200430955T patent/SI1604991T1/sl unknown
- 2004-03-11 CN CNA2008101445581A patent/CN101357134A/zh active Pending
- 2004-03-11 NZ NZ542150A patent/NZ542150A/xx not_active IP Right Cessation
- 2004-03-11 RU RU2005131839/15A patent/RU2334517C2/ru active
- 2004-03-11 AT AT04719589T patent/ATE408408T1/de active
- 2004-03-11 AU AU2004220205A patent/AU2004220205B2/en not_active Ceased
- 2004-03-11 PT PT04719589T patent/PT1604991E/pt unknown
- 2004-03-12 TW TW093106702A patent/TW200503720A/zh not_active IP Right Cessation
-
2008
- 2008-10-06 CY CY20081101101T patent/CY1108395T1/el unknown
-
2017
- 2017-02-17 US US15/435,493 patent/US9814724B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ATE408408T1 (de) | 2008-10-15 |
| PL1604991T3 (pl) | 2009-02-27 |
| EP1604991A4 (en) | 2006-05-03 |
| AU2004220205A1 (en) | 2004-09-23 |
| EP1604991A1 (en) | 2005-12-14 |
| US9814724B2 (en) | 2017-11-14 |
| US9611227B2 (en) | 2017-04-04 |
| KR100812693B1 (ko) | 2008-03-13 |
| AU2004220205B2 (en) | 2010-06-17 |
| DE602004016636D1 (de) | 2008-10-30 |
| WO2004081012A1 (ja) | 2004-09-23 |
| CN1761665A (zh) | 2006-04-19 |
| NZ542150A (en) | 2009-09-25 |
| CY1108395T1 (el) | 2014-02-12 |
| ES2312978T3 (es) | 2009-03-01 |
| US20170157131A1 (en) | 2017-06-08 |
| DK1604991T3 (da) | 2009-01-05 |
| MXPA05009781A (es) | 2005-10-26 |
| RU2334517C2 (ru) | 2008-09-27 |
| CN101357134A (zh) | 2009-02-04 |
| SI1604991T1 (sl) | 2009-02-28 |
| TW200503720A (en) | 2005-02-01 |
| CA2518195A1 (en) | 2004-09-23 |
| RU2005131839A (ru) | 2006-02-10 |
| EP1604991B1 (en) | 2008-09-17 |
| PT1604991E (pt) | 2008-10-27 |
| TWI295173B (pt) | 2008-04-01 |
| JP4610481B2 (ja) | 2011-01-12 |
| JPWO2004081012A1 (ja) | 2006-06-08 |
| US20060116345A1 (en) | 2006-06-01 |
| CA2518195C (en) | 2009-07-07 |
| KR20050106119A (ko) | 2005-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108395T1 (el) | Ουσια επαυξησης της δρασης εναντι ογκων και παραγοντας εναντι ογκων | |
| ATE428411T1 (de) | Hdl-verstärkende kombinationstherapie-komplexe | |
| WO2007075554A3 (en) | Combination of igfr inhibitor and anti-cancer agent | |
| WO2003030908A3 (en) | Inhibitors of the egf receptor for the treatment of thyroid cancer | |
| TW200637828A (en) | Novel cis-imidazolines | |
| ATE411022T1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
| UA91006C2 (ru) | Способ получения аминокротонильных соединений | |
| EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
| IS6925A (is) | Aðferð og skömmtunarform til meðhöndlunar æxla með gjöf tegafúrs, úracíls, fólínsýru, paclítaxels og karbóplatíns | |
| IL162384A0 (en) | Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases | |
| EP1695969A4 (en) | ALPHA-AMINO-ACID DERIVATIVES AND THEIR USE AS MEDICINE | |
| BRPI0408238A (pt) | anticorpo, método de detectar cáncer, conjunto para detecção de cáncer, e, composição farmacêutica para tratar cáncer | |
| WO2005123068A3 (en) | Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor | |
| WO2008109521A3 (en) | Method of treatment using atranorin | |
| MY140563A (en) | Antitumor effect potentiator, antitumor preparation | |
| CY1106385T1 (el) | Χρηση παραγωγων της εποθειλονης για τη θepαπεια του υπepπαραθυρεοειδισμου | |
| WO2006135796A3 (en) | Crystalline forms of a pyrrolotriazine compound | |
| DE60309926D1 (de) | Steroid-verbindungen mit anti-tumoraler wirkung | |
| WO2007017652A3 (en) | Arylakylamines for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |